Thailand Point Of Care Testing Poct Market
市场规模（十亿美元）
CAGR :
% 
USD
139.18 Million
USD
251.94 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 139.18 Million |
 Market Size (Forecast Year) |
USD 251.94 Million |
 CAGR |
% |
| Major Markets Players |
|
泰國即時診斷 (POCT) 市場，按產品（血糖監測產品、心臟代謝檢測產品、傳染病檢測產品、懷孕和生育檢測產品、腫瘤/癌症標記檢測產品、尿液分析檢測產品、膽固醇檢測產品、血液學檢測產品、藥物濫用檢測產品、糞便潛血檢測產品、快速凝固檢測和其他 POC產品）、應用（血糖心臟監測、血液學、凝血、全血分析、生命徵象監測、非侵入性血氧飽和度監測、非侵入性二氧化碳分壓監測、輸血等）、平台（橫向流動分析/免疫層析測試、試紙、分子診斷、免疫分析和微流體）、處方模式（處方檢測和 OTC檢測）、檢測類型（免疫分析、細胞分析、核酸酸性擴增測試、臨床化學測定和血液學）、最終用戶部門（醫院、診所、實驗室、家庭護理、門診手術中心等）、分銷管道（直銷藥局和零售藥局）——行業趨勢和 2030 年預測。
泰國即時診斷檢測（POCT）市場分析及規模
即時檢驗 (POCT) 的特徵是可以在靠近患者的地方進行的檢測，可以立即做出醫療決策，包括結果和監測。即時檢驗 (POCT) 也稱為患者追蹤檢測。它使醫生能夠在幾分鐘內（而不是幾小時）準確地測量即時、實驗室品質的診斷結果。目前，有各種產品可以提供快速且準確的結果並幫助患者獲得更好的治療效果，預計這將為即時檢驗市場提供各種其他機會。然而，實驗室結果缺乏一致性和即時檢驗產品成本高昂預計將在預測期內抑制市場成長。主要市場參與者的存在為市場成長提供了機遇，而缺乏訓練有素的專業人員則對市場成長構成了挑戰。
根據 Data Bridge Market Research 分析，泰國即時診斷檢測 (POCT) 市場規模在 2022 年為 1.3918 億美元，到 2030 年將增至 2.5194 億美元，預計預測期內的複合年增長率為 7.70%。由於糖尿病盛行率較高，「血糖監測產品」在泰國即時診斷檢測 (POCT) 市場的產品領域佔據主導地位。除了對市場價值、成長率、細分市場、地理覆蓋範圍和主要參與者等市場情景的洞察外，Data Bridge Market Research 整理的市場報告還包括深度專家分析、病患流行病學、通路分析、定價分析和監管框架。
泰國即時檢驗（POCT）市場範圍與細分
|
報告指標 |
細節 |
|
預測期 |
2023年至2030年 |
|
基準年 |
2022 |
|
歷史歲月 |
2021（可自訂為2015-2020） |
|
定量單位 |
收入（百萬美元）、銷售（單位）、定價（美元） |
|
涵蓋的領域 |
產品（血糖監測產品、心臟代謝檢測產品、傳染病檢測產品、懷孕和生育檢測產品、腫瘤/癌症標記檢測產品、尿液分析檢測產品、膽固醇檢測產品、血液學檢測產品、藥物濫用檢測產品、糞便潛血檢測產品、快速凝血檢測和其他 POC產品）、應用（血糖心臟監測、血液學、凝血、全血分析、生命徵象監測、非侵入性血氧飽和度監測、非侵入性二氧化碳分壓監測、輸血等）、平台（橫向流動分析/免疫層析檢測、試紙、分子診斷、免疫分析和微流體）、處方模式（處方檢測和 OTC檢測）、檢測類型（免疫分析、細胞分析、核酸擴增檢測、臨床化學分析和血液學）、最終用戶部門（醫院、診所、實驗室、家庭護理、門診手術中心等）、分銷管道（直銷藥局和零售藥局） |
|
覆蓋國家 |
泰國 |
|
涵蓋的市場參與者 |
Bio-Rad Laboratories, Inc.（美國）、bioMérieux SA（法國）、Trinity Biotech（愛爾蘭）、BD（美國）、EKF Diagnostics（英國）、Abbott（美國）、Quidel Corporation（美國）、Sienco, Inc.（美國）、Danaher（美國）、Cbio Diagnostics, Inc.（美國） Diagnostics（美國）、AccuBioTech Co., Ltd（中國）、Beckman Coulter, Inc.（美國）、F. Hoffmann-La Roche Ltd（瑞士）、Sekisui Diagnostics（日本）、Instrumentation Laboratory (A Subsidiary Of Wergfen)（美國）、廈門百、生物科技有限公司（中國門泰） |
|
市場機會 |
|
市場定義
即時檢驗 (POCT) 是指在患者附近或患者所在位置進行的醫學診斷檢測，通常在傳統實驗室環境之外進行。它通常可在幾分鐘內快速獲得結果，從而幫助醫生立即做出臨床決策。 POCT 設備便攜且使用者友好，方便醫護人員在床邊、診所甚至家中進行檢測。常見應用包括血糖監測、傳染病檢測和妊娠檢測。
泰國即時檢驗（POCT）市場動態
驅動程式
- 對診斷便利性的需求不斷增長
患者和醫療保健提供者尋求便捷的檢測方式，而 POCT 設備通常便攜、用戶友好，並且只需要極少的樣品製備。
- 慢性病管理需求不斷成長
糖尿病和心血管疾病等慢性病的盛行率不斷上升，推動了對定期監測的需求，而 POCT 則有助於
機會
- 增加醫療保健的機會
隨著即時診斷 (POCT) 設備越來越普及且價格實惠，它們可以幫助提高醫療服務的可近性，尤其是在泰國農村和服務不足的地區。這可以改善醫療效果並縮小醫療差距。
- 早期疾病檢測
POCT設備可以快速且方便地檢測各種疾病和病症，包括傳染病、糖尿病和心血管疾病。這些疾病的早期發現和診斷可以帶來更有效的治療和管理，並有可能長期降低醫療成本。
限制/挑戰
- 監理合規
滿足 POCT 設備的嚴格監管要求可能非常複雜且耗時，從而導致產品批准和市場准入延遲
- 高成本
購買和實施 POCT 設備的初始成本以及持續的營運費用可能會成為醫療機構的障礙，尤其是在資源有限的環境中
這份即時診斷檢測 (POCT) 市場報告詳細介紹了最新發展動態、貿易法規、進出口分析、生產分析、價值鏈優化、市場份額、國內和本地市場參與者的影響，並分析了新興收入來源、市場法規變化、戰略市場增長分析、市場規模、品類市場增長、應用領域和市場主導地位、產品審批、產品發布、戰略市場增長分析、市場規模、品類市場增長、應用領域和市場主導地位、產品地審批、產品發布、戰略市場增長分析以及市場創新領域的領域。如需了解更多關於即時診斷檢測 (POCT) 市場的信息，請聯繫 Data Bridge 市場研究公司以獲取分析師簡報，我們的團隊將協助您做出明智的市場決策，以實現市場成長。
最新動態
- 2020年，貝克曼庫爾特公司推出了一套全面的實驗室自動化解決方案，為週轉時間樹立了新的標竿。此自動化解決方案服務將有助於獲得高品質的結果，並改善實驗室運作。這將有助於公司建立新的優質服務標準，從而在未來創造更多收入。
- 2017年，積水診斷公司宣布經銷Mesa Biotech的甲型/乙型流感分子診斷即時分子診斷系統。此系統可幫助醫生在即時診斷中快速診斷傳染病，並提高靈敏度。這將有助於公司增加收入。
泰國即時檢驗（POCT）市場範圍
泰國即時檢驗 (POCT) 市場根據產品、應用、平台、處方模式、檢測類型、最終用戶和分銷管道進行細分。這些細分市場的成長將有助於您分析行業中成長乏力的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
產品
- 血糖監測產品
- 心臟代謝測試產品
- 傳染病檢測產品
- 妊娠和生育測試產品
- 腫瘤/癌症標記檢測產品
- 尿液分析檢測產品
- 膽固醇檢測產品
- 血液學檢測產品
- 藥物濫用檢測產品
- 糞便隱血檢測產品
- 快速凝血檢測
- 其他 POC 產品
應用
- 血糖心臟監測
- 血液學
- 凝血
- 全血分析
- 生命徵象監測
- 非侵入性血氧監測
- 無創 Pco2 監測
- 輸血
- 其他的
平台
- 橫向流動分析/免疫層析測試
- 量油尺
- 分子診斷
- 免疫測定
- 微流體
處方模式
- 基於處方的測試
- OTC測試
測試類型
- 免疫測定
- 基於細胞的檢測
- 核酸擴增檢測
- 臨床化學檢測
- 血液學
最終用戶
- 醫院
- 診所
- 實驗室
- 居家護理
- 門診手術中心
- 其他的
分銷管道
- 直接的
- 零售藥局
競爭格局和泰國即時診斷檢測（POCT）市場份額分析
泰國即時診斷檢測 (POCT) 市場競爭格局提供了按競爭對手劃分的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投入、新市場計劃、泰國業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度以及應用主導地位。以上提供的數據僅與公司在泰國即時診斷檢測 (POCT) 市場的重點相關。
泰國即時診斷檢測 (POCT) 市場的一些主要參與者包括：
- Bio-Rad Laboratories, Inc.（美國）
- 生物梅里埃公司（法國）
- Trinity Biotech（愛爾蘭）
- BD（碧迪公司）（美國）
- EKF診斷（英國）
- 雅培（美國）
- Quidel Corporation（美國）
- Sienco, Inc.（美國）
- 丹納赫（美國）
- Chembio Diagnostics Systems, Inc.（美國）
- Nova Biomedical（美國）
- PTS Diagnostics（美國）
- AccuBioTech股份有限公司 (中國)
- 貝克曼庫爾特公司（美國）
- F. Hoffmann-La Roche Ltd（瑞士）
- 積水診斷（日本）
- 儀器實驗室（Werfen 子公司）（美國）
- 廈門寶泰生物科技有限公司 (中國)
- 富士膠片泰國有限公司（泰國）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THAILAND POINT-OF-CARE-TESTING (POCT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE THAILAND POINT-OF-CARE-TESTING (POCT) SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 OPPUTUNITY MAP ANALYSIS
13 HEALTHCARE ECONOMY
13.1 HEALTHCARE EXPENDITURE
13.2 CAPITAL EXPENDITURE
13.3 CAPEX TRENDS
13.4 CAPEX ALLOCATION
13.5 FUNDING SOURCES
13.6 INDUSTRY BENCHMARKS
13.7 GDP RATION IN OVERALL GDP
13.8 HEALTHCARE SYSTEM STRUCTURE
13.9 GOVERNMENT POLICIES
13.1 ECONOMIC DEVELOPMENT
14 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRODUCT TYPE
14.1 OVERVIEW
14.2 CARDIOMETABOLIC MONITORING PRODUCTS
14.2.1 CARDIAC MARKER TESTING PRODUCTS
14.2.1.1. HSTNL
14.2.1.1.1. MARKET VALUE (USD MILLION)
14.2.1.1.2. MARKET VOLUME (UNITS)
14.2.1.1.3. AVERAGE SELLING PRICE (USD)
14.2.1.2. BNP
14.2.1.2.1. MARKET VALUE (USD MILLION)
14.2.1.2.2. MARKET VOLUME (UNITS)
14.2.1.2.3. AVERAGE SELLING PRICE (USD)
14.2.1.3. D-DIMER
14.2.1.3.1. MARKET VALUE (USD MILLION)
14.2.1.3.2. MARKET VOLUME (UNITS)
14.2.1.3.3. AVERAGE SELLING PRICE (USD)
14.2.1.4. CK-MB
14.2.1.4.1. MARKET VALUE (USD MILLION)
14.2.1.4.2. MARKET VOLUME (UNITS)
14.2.1.4.3. AVERAGE SELLING PRICE (USD)
14.2.1.5. MYOGLOBIN
14.2.1.5.1. MARKET VALUE (USD MILLION)
14.2.1.5.2. MARKET VOLUME (UNITS)
14.2.1.5.3. AVERAGE SELLING PRICE (USD)
14.2.1.6. OTHERS
14.2.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
14.2.2.1. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES
14.2.2.1.1. CARTRIDGES
14.2.2.1.1.1 MARKET VALUE (USD MILLION)
14.2.2.1.1.2 MARKET VOLUME (UNITS)
14.2.2.1.1.3 AVERAGE SELLING PRICE (USD)
14.2.2.1.2. REAGENTS
14.2.2.1.2.1 MARKET VALUE (USD MILLION)
14.2.2.1.2.2 MARKET VOLUME (UNITS)
14.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
14.2.2.2. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS
14.2.2.2.1. BENCHTOP
14.2.2.2.1.1 BLOOD GAS ANALYZERS
14.2.2.2.1.1.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.1.2. MARKET VOLUME (UNITS)
14.2.2.2.1.1.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.1.2 ELECTROLYTE ANALYZERS
14.2.2.2.1.2.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.2.2. MARKET VOLUME (UNITS)
14.2.2.2.1.2.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.1.3 COMBINED ANALYZERS
14.2.2.2.1.3.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.3.2. MARKET VOLUME (UNITS)
14.2.2.2.1.3.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2. PORTABLE
14.2.2.2.2.1 BLOOD GAS ANALYZERS
14.2.2.2.2.1.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.1.2. MARKET VOLUME (UNITS)
14.2.2.2.2.1.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2.2 ELECTROLYTE ANALYZERS
14.2.2.2.2.2.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.2.2. MARKET VOLUME (UNITS)
14.2.2.2.2.2.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2.3 COMBINED ANALYZERS
14.2.2.2.2.3.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.3.2. MARKET VOLUME (UNITS)
14.2.2.2.2.3.3. AVERAGE SELLING PRICE (USD)
14.2.3 HBA1C TESTING PRODUCTS
14.2.3.1. HBA1C TESTING INSTRUMENTS
14.2.3.1.1. MARKET VALUE (USD MILLION)
14.2.3.1.2. MARKET VOLUME (UNITS)
14.2.3.1.3. AVERAGE SELLING PRICE (USD)
14.2.3.2. HBA1C TESTING CONSUMABLES
14.2.3.2.1. MARKET VALUE (USD MILLION)
14.2.3.2.2. MARKET VOLUME (UNITS)
14.2.3.2.3. AVERAGE SELLING PRICE (USD)
14.2.4 POC ANALYSER
14.2.4.1. MARKET VALUE (USD MILLION)
14.2.4.2. MARKET VOLUME (UNITS)
14.2.4.3. AVERAGE SELLING PRICE (USD)
14.2.5 ECG DEVICE
14.2.5.1. RESTING ECG DEVICES
14.2.5.1.1. MARKET VALUE (USD MILLION)
14.2.5.1.2. MARKET VOLUME (UNITS)
14.2.5.1.3. AVERAGE SELLING PRICE (USD)
14.2.5.2. STRESS ECG DEVICES
14.2.5.2.1. MARKET VALUE (USD MILLION)
14.2.5.2.2. MARKET VOLUME (UNITS)
14.2.5.2.3. AVERAGE SELLING PRICE (USD)
14.2.5.3. HOLTER MONITORS
14.2.5.3.1. MARKET VALUE (USD MILLION)
14.2.5.3.2. MARKET VOLUME (UNITS)
14.2.5.3.3. AVERAGE SELLING PRICE (USD)
14.2.6 OTHERS
14.3 GLUCOSE MONITORING PRODUCTS
14.3.1 STRIPS
14.3.1.1. MARKET VALUE (USD MILLION)
14.3.1.2. MARKET VOLUME (UNITS)
14.3.1.3. AVERAGE SELLING PRICE (USD)
14.3.2 METERS
14.3.2.1. MARKET VALUE (USD MILLION)
14.3.2.2. MARKET VOLUME (UNITS)
14.3.2.3. AVERAGE SELLING PRICE (USD)
14.3.3 LANCETS & LANCING DEVICES
14.3.3.1. MARKET VALUE (USD MILLION)
14.3.3.2. MARKET VOLUME (UNITS)
14.3.3.3. AVERAGE SELLING PRICE (USD)
14.4 INFECTIOUS DISEASE TESTING PRODUCTS
14.4.1 INFLUENZA TESTING PRODUCTS
14.4.1.1. TRADITIONAL DIAGNOSTIC TEST
14.4.1.1.1. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
14.4.1.1.1.1 MARKET VALUE (USD MILLION)
14.4.1.1.1.2 MARKET VOLUME (UNITS)
14.4.1.1.1.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.2. DIRECT FLUORESCENT ANTIBODY TEST (DFAT)
14.4.1.1.2.1 MARKET VALUE (USD MILLION)
14.4.1.1.2.2 MARKET VOLUME (UNITS)
14.4.1.1.2.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.3. VIRAL CULTURE
14.4.1.1.3.1 MARKET VALUE (USD MILLION)
14.4.1.1.3.2 MARKET VOLUME (UNITS)
14.4.1.1.3.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.4. SEROLOGICAL ASSAY
14.4.1.1.4.1 MARKET VALUE (USD MILLION)
14.4.1.1.4.2 MARKET VOLUME (UNITS)
14.4.1.1.4.3 AVERAGE SELLING PRICE (USD)
14.4.1.2. MOLECULAR DIAGNOSTIC ASSAY
14.4.1.2.1. RT-PCR
14.4.1.2.1.1 MARKET VALUE (USD MILLION)
14.4.1.2.1.2 MARKET VOLUME (UNITS)
14.4.1.2.1.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.2. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
14.4.1.2.2.1 MARKET VALUE (USD MILLION)
14.4.1.2.2.2 MARKET VOLUME (UNITS)
14.4.1.2.2.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.3. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)
14.4.1.2.3.1 MARKET VALUE (USD MILLION)
14.4.1.2.3.2 MARKET VOLUME (UNITS)
14.4.1.2.3.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.4. SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
14.4.1.2.4.1 MARKET VALUE (USD MILLION)
14.4.1.2.4.2 MARKET VOLUME (UNITS)
14.4.1.2.4.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.5. OTHERS
14.4.2 HIV TESTING PRODUCTS
14.4.2.1. TESTING EQUIPMENT
14.4.2.1.1. MARKET VALUE (USD MILLION)
14.4.2.1.2. MARKET VOLUME (UNITS)
14.4.2.1.3. AVERAGE SELLING PRICE (USD)
14.4.2.2. TESTING REAGENT
14.4.2.2.1. MARKET VALUE (USD MILLION)
14.4.2.2.2. MARKET VOLUME (UNITS)
14.4.2.2.3. AVERAGE SELLING PRICE (USD)
14.4.3 HEPATITIS C TESTING PRODUCTS
14.4.3.1. HCV ANTIBODY TESTS
14.4.3.1.1. MARKET VALUE (USD MILLION)
14.4.3.1.2. MARKET VOLUME (UNITS)
14.4.3.1.3. AVERAGE SELLING PRICE (USD)
14.4.3.2. HCV VIRAL LOAD TESTS
14.4.3.2.1. MARKET VALUE (USD MILLION)
14.4.3.2.2. MARKET VOLUME (UNITS)
14.4.3.2.3. AVERAGE SELLING PRICE (USD)
14.4.3.3. OTHER TESTS
14.4.4 SEXUALLY TRANSMITTED DISEASE (STD) TESTING
14.4.4.1. NAAT-BASED SYSTEMS
14.4.4.1.1. MARKET VALUE (USD MILLION)
14.4.4.1.2. MARKET VOLUME (UNITS)
14.4.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.4.2. NON–NAAT-BASED SYSTEMS
14.4.4.2.1. MARKET VALUE (USD MILLION)
14.4.4.2.2. MARKET VOLUME (UNITS)
14.4.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.5 HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING
14.4.5.1. MARKET VALUE (USD MILLION)
14.4.5.2. MARKET VOLUME (UNITS)
14.4.5.3. AVERAGE SELLING PRICE (USD)
14.4.6 RESPIRATORY INFECTION TESTING PRODUCTS
14.4.6.1. MARKET VALUE (USD MILLION)
14.4.6.2. MARKET VOLUME (UNITS)
14.4.6.3. AVERAGE SELLING PRICE (USD)
14.4.7 TROPICAL DISEASE TESTING PRODUCTS
14.4.7.1. MARKET VALUE (USD MILLION)
14.4.7.2. MARKET VOLUME (UNITS)
14.4.7.3. AVERAGE SELLING PRICE (USD)
14.4.8 COVID-19
14.4.8.1. MARKET VALUE (USD MILLION)
14.4.8.2. MARKET VOLUME (UNITS)
14.4.8.3. AVERAGE SELLING PRICE (USD)
14.4.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
14.5 COAGULATION MONITORING PRODUCTS
14.5.1 ANTICOAGULATION MONITORING DEVICES
14.5.1.1. PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES
14.5.1.1.1. MARKET VALUE (USD MILLION)
14.5.1.1.2. MARKET VOLUME (UNITS)
14.5.1.1.3. AVERAGE SELLING PRICE (USD)
14.5.1.2. ACTIVATED CLOTTING TIME (ACT)
14.5.1.2.1. MARKET VALUE (USD MILLION)
14.5.1.2.2. MARKET VOLUME (UNITS)
14.5.1.2.3. AVERAGE SELLING PRICE (USD)
14.5.1.3. ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT)
14.5.1.3.1. MARKET VALUE (USD MILLION)
14.5.1.3.2. MARKET VOLUME (UNITS)
14.5.1.3.3. AVERAGE SELLING PRICE (USD)
14.5.2 PLATELET FUNCTION MONITORING DEVICES
14.5.2.1. MARKET VALUE (USD MILLION)
14.5.2.2. MARKET VOLUME (UNITS)
14.5.2.3. AVERAGE SELLING PRICE (USD)
14.5.3 VISCOELASTIC COAGULATION MONITORING DEVICES
14.5.3.1. THROMBOELASTOGRAPHY (TEG)
14.5.3.1.1. MARKET VALUE (USD MILLION)
14.5.3.1.2. MARKET VOLUME (UNITS)
14.5.3.1.3. AVERAGE SELLING PRICE (USD)
14.5.3.2. ROTATIONAL THROMBOELASTOMETRY (ROTEM)
14.5.3.2.1. MARKET VALUE (USD MILLION)
14.5.3.2.2. MARKET VOLUME (UNITS)
14.5.3.2.3. AVERAGE SELLING PRICE (USD)
14.5.4 OTHERS
14.6 PREGNANCY & FERTILITY TESTING PRODUCTS
14.6.1 PREGNANCY TESTING PRODUCTS
14.6.1.1. PREGNANCY TESTING , BY PRODUCT TYPE
14.6.1.1.1. STRIPS/ DIP STICKS AND CARDS
14.6.1.1.1.1 MARKET VALUE (USD MILLION)
14.6.1.1.1.2 MARKET VOLUME (UNITS)
14.6.1.1.1.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.2. MID STREAM DEVICES
14.6.1.1.2.1 MARKET VALUE (USD MILLION)
14.6.1.1.2.2 MARKET VOLUME (UNITS)
14.6.1.1.2.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.3. CASSETTES
14.6.1.1.3.1 MARKET VALUE (USD MILLION)
14.6.1.1.3.2 MARKET VOLUME (UNITS)
14.6.1.1.3.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.4. DIGITAL DEVICES
14.6.1.1.4.1 MARKET VALUE (USD MILLION)
14.6.1.1.4.2 MARKET VOLUME (UNITS)
14.6.1.1.4.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.5. LINE-INDICATOR DEVICES
14.6.1.1.5.1 MARKET VALUE (USD MILLION)
14.6.1.1.5.2 MARKET VOLUME (UNITS)
14.6.1.1.5.3 AVERAGE SELLING PRICE (USD)
14.6.1.2. PREGNANCY TESTING, BY TEST TYPE
14.6.1.2.1. FSH URINE TEST
14.6.1.2.1.1 MARKET VALUE (USD MILLION)
14.6.1.2.1.2 MARKET VOLUME (UNITS)
14.6.1.2.1.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.2. LUTEINIZING HORMONE (LH) URINE TEST
14.6.1.2.2.1 MARKET VALUE (USD MILLION)
14.6.1.2.2.2 MARKET VOLUME (UNITS)
14.6.1.2.2.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD/SERUM TEST
14.6.1.2.3.1 MARKET VALUE (USD MILLION)
14.6.1.2.3.2 MARKET VOLUME (UNITS)
14.6.1.2.3.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.4. HCG URINE TEST
14.6.1.2.4.1 MARKET VALUE (USD MILLION)
14.6.1.2.4.2 MARKET VOLUME (UNITS)
14.6.1.2.4.3 AVERAGE SELLING PRICE (USD)
14.6.2 FERTILITY TESTING PRODUCTS
14.6.2.1. HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST
14.6.2.1.1. MARKET VALUE (USD MILLION)
14.6.2.1.2. MARKET VOLUME (UNITS)
14.6.2.1.3. AVERAGE SELLING PRICE (USD)
14.6.2.2. FSH URINE TEST
14.6.2.2.1. MARKET VALUE (USD MILLION)
14.6.2.2.2. MARKET VOLUME (UNITS)
14.6.2.2.3. AVERAGE SELLING PRICE (USD)
14.6.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD TEST
14.6.2.3.1. MARKET VALUE (USD MILLION)
14.6.2.3.2. MARKET VOLUME (UNITS)
14.6.2.3.3. AVERAGE SELLING PRICE (USD)
14.6.2.4. LUTEINIZING HORMONE (LH) URINE TEST
14.6.2.4.1. MARKET VALUE (USD MILLION)
14.6.2.4.2. MARKET VOLUME (UNITS)
14.6.2.4.3. AVERAGE SELLING PRICE (USD)
14.7 TUMOR/CANCER MARKER TESTING PRODUCTS
14.7.1 MARKET VALUE (USD MILLION)
14.7.2 MARKET VOLUME (UNITS)
14.7.3 AVERAGE SELLING PRICE (USD)
14.8 URINALYSIS TESTING PRODUCTS
14.8.1 POC URINE STRIP SELF-TESTING
14.8.1.1. MARKET VALUE (USD MILLION)
14.8.1.2. MARKET VOLUME (UNITS)
14.8.1.3. AVERAGE SELLING PRICE (USD)
14.8.2 POC URINE TEST STRIP PROFESSIONAL TESTING
14.8.2.1. MARKET VALUE (USD MILLION)
14.8.2.2. MARKET VOLUME (UNITS)
14.8.2.3. AVERAGE SELLING PRICE (USD)
14.9 CHOLESTEROL TESTING PRODUCTS
14.9.1 INSTRUMENTS
14.9.1.1. TABLE-TOP ANALYZERS
14.9.1.1.1. MARKET VALUE (USD MILLION)
14.9.1.1.2. MARKET VOLUME (UNITS)
14.9.1.1.3. AVERAGE SELLING PRICE (USD)
14.9.1.2. HAND-HELD ANALYZERS
14.9.1.2.1. MARKET VALUE (USD MILLION)
14.9.1.2.2. MARKET VOLUME (UNITS)
14.9.1.2.3. AVERAGE SELLING PRICE (USD)
14.9.2 TESTING KITS
14.9.2.1. MARKET VALUE (USD MILLION)
14.9.2.2. MARKET VOLUME (UNITS)
14.9.2.3. AVERAGE SELLING PRICE (USD)
14.1 HEMATOLOGY TESTING PRODUCTS
14.10.1 MARKET VALUE (USD MILLION)
14.10.2 MARKET VOLUME (UNITS)
14.10.3 AVERAGE SELLING PRICE (USD)
14.11 DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS
14.11.1 DOA ANALYSERS
14.11.1.1. IMMUNOASSAYS
14.11.1.1.1. MARKET VALUE (USD MILLION)
14.11.1.1.2. MARKET VOLUME (UNITS)
14.11.1.1.3. AVERAGE SELLING PRICE (USD)
14.11.1.2. CHROMATOGRAPHIC DEVICES
14.11.1.2.1. MARKET VALUE (USD MILLION)
14.11.1.2.2. MARKET VOLUME (UNITS)
14.11.1.2.3. AVERAGE SELLING PRICE (USD)
14.11.1.3. BREATH ANALYSERS
14.11.1.3.1. MARKET VALUE (USD MILLION)
14.11.1.3.2. MARKET VOLUME (UNITS)
14.11.1.3.3. AVERAGE SELLING PRICE (USD)
14.11.2 RAPID TESTING DEVICES
14.11.2.1. URINE TESTING DEVICES
14.11.2.1.1. MARKET VALUE (USD MILLION)
14.11.2.1.2. MARKET VOLUME (UNITS)
14.11.2.1.3. AVERAGE SELLING PRICE (USD)
14.11.2.2. ORAL FLUID TESTING DEVICES
14.11.2.2.1. MARKET VALUE (USD MILLION)
14.11.2.2.2. MARKET VOLUME (UNITS)
14.11.2.2.3. AVERAGE SELLING PRICE (USD)
14.11.3 OTHERS
14.12 FECAL OCCULT TESTING PRODUCTS
14.12.1 GUAIAC FOB STOOL TEST
14.12.1.1. MARKET VALUE (USD MILLION)
14.12.1.2. MARKET VOLUME (UNITS)
14.12.1.3. AVERAGE SELLING PRICE (USD)
14.12.2 IMMUNO-FOB AGGLUTINATION TEST
14.12.2.1. MARKET VALUE (USD MILLION)
14.12.2.2. MARKET VOLUME (UNITS)
14.12.2.3. AVERAGE SELLING PRICE (USD)
14.12.3 LATERAL FLOW IMMUNO-FOB TEST
14.12.3.1. MARKET VALUE (USD MILLION)
14.12.3.2. MARKET VOLUME (UNITS)
14.12.3.3. AVERAGE SELLING PRICE (USD)
14.12.4 IMMUNO-FOB ELISA TEST
14.12.4.1. MARKET VALUE (USD MILLION)
14.12.4.2. MARKET VOLUME (UNITS)
14.12.4.3. AVERAGE SELLING PRICE (USD)
14.13 OTHER POC PRODUCTS
15 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY APPLICATION
15.1 OVERVIEW
15.2 BLOOD TRANSFUSION
15.3 CARDIAC MONITORING
15.4 COAGULATION
15.5 BLOOD GLUCOSE
15.6 HAEMATOLOGY
15.7 NON- INVASIVE SPO2 MONITORING
15.8 NON- INVASIVE PCO2 MONITORING
15.9 WHOLE BLOOD ANALYSIS
15.1 VITAL SIGN MONITORING
15.11 OTHERS
16 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PLATFORM
16.1 OVERVIEW
16.2 LATERAL FLOW ASSAYS
16.3 IMMUNOCHROMATOGRAPHY TESTS
16.4 DIPSTICKS
16.5 MICROFLUIDICS
16.6 MOLECULAR DIAGNOSTICS
16.7 IMMUNOASSAYS
16.8 CLINICAL CHEMISTRY ASSAYS
16.9 HEMATOLOGY
16.1 OTHERS
17 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRESCRIPTION MODE
17.1 OVERVIEW
17.2 PRESCRIPTION-BASED TESTING
17.3 OTC TESTING
18 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY TESTING LOCATION
18.1 OVERVIEW
18.2 LABORATORY BASED POINT-OF-CARE-TESTING (POCT)
18.3 AT-HOME POINT-OF-CARE-TESTING (POCT)
19 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY END USER
19.1 OVERVIEW
19.2 HOSPITAL
19.2.1 PRIVATE
19.2.1.1. TIER 1
19.2.1.2. TIER 2
19.2.1.3. TIER 3
19.2.2 PUBLIC
19.2.2.1. TIER 1
19.2.2.2. TIER 2
19.2.2.3. TIER 3
19.3 CLINICS
19.4 LABORATORIES
19.5 PATHOLOGY LABS
19.6 DIAGNOSTIC CENTER
19.7 HOME CARE
19.8 AMBULATORY SURGERY CENTERS
19.9 ELDERLY CARE CENTERS
19.1 OTHERS
20 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.4 ONLINE SALES
20.5 OTHERS
21 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , SWOT AND DBMR ANALYSIS
22 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: THAILAND
22.2 MERGERS & ACQUISITIONS
22.3 NEW PRODUCT DEVELOPMENT & APPROVALS
22.4 EXPANSIONS
22.5 REGULATORY CHANGES
22.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY REGION
Thailand Point-of-Care-Testing (POCT) Market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY PROFILE
24.1 F. HOFFMANN-LA ROCHE LTD
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 SIEMENS HEALTHCARE GMBH
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 ABBOTT
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 BIOMÉRIEUX
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 ACON LABORATORIES, INC.
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 BIO-RAD LABORATORIES, INC
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 WERFEN
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 NOVA BIOMEDICAL
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 PTS DIAGNOSTICS
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 SEKISUI DIAGNOSTICS
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 TRINITY BIOTECH
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 DANAHER
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 THERMO FISHER SCIENTIFIC INC
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 MERIDIAN DIAGNOSTICS
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 BD
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 SYSMEX (THAILAND) CO., LTD
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 FUJIFILM THAILAND LTD.
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
